Mosca, L. C-reactive protein — to screen or not to screen? N. Engl. J. Med., 347:1615–16, 2002.
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P. et al. For the reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) investiga¬tors statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med., 352:29–38, 2005.
Ridker, P. M., Rifal, N., Rose, L. et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med., 347:1557–65, 2002.
Ridker, P. M., Cannon, C. P., Morrow, D. et al. For the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) Investigator: C-reactive protein levels and outcomes after statin therapy. N. Eng. J. Med., 352:20–28, 2005.
Rossi, E. C-reactive protein and progress of atherosclerosis. Lancet, 360:1436, 2002.
Tall, A. R. C-reactive protein reassessed. N. Engl. J. Med., 350: 1450–1452, 2004.

Страницы: 1 | 2